Literature DB >> 16082590

Different concentrations of various radiopharmaceuticals in the two main liver lobes: a preliminary study in clinical patients.

Hans Jacobsson1, Eduard Jonas, Per M Hellström, Stig A Larsson.   

Abstract

BACKGROUND: At clinical scintigraphic examinations of the abdomen using single photon emission computed tomography (SPECT), we have observed a different distribution between the left and right main liver lobes of various radiopharmaceuticals. This was studied retrospectively in clinical patients.
METHODS: Examinations with [123I]-metaiodobenzylguanidine MIBG; (n=19), a 99mTc-labelled monoclonal antibody against granulocytes (n=18), and 111In-pentetreotide (n=26) were assessed. There was no known history of, or risk factor for liver disease, and all lobes showed a uniform activity distribution. Twenty healthy volunteers underwent consecutive examinations with 99mTc-dimethyliminodiacetic acid (HIDA). The activity ratios between the left and right main liver lobes were calculated from the transverse tomographic (SPECT) sections.
RESULTS: The left: right lobar activity ratio for [123I]-MIBG was (mean+/-SD) 1.25+/-0.21 (null hypothesis=1.00; P<0.001); for the antibody, acquisition after 3-5 h was 0.98+/-0.06 (NS) and after 20-24 h, 0.99+/-0.11 (NS); for 111In-pentetreotide, 0.90+/-0.09 (P<0.001); for 99mTc-HIDA, immediate acquisition, 0.68+/-0.12 (P<0.001) and acquisition at 7 min, 0.66+/-0.12 (P<0.001).
CONCLUSIONS: The differences in tracer uptake between the liver lobes cannot be caused only by differences in blood flow. One explanation of the higher uptake of [123I]-MIBG by the left lobe may be a greater presence of catecholamines and a higher sympathetic nerve density in this liver portion. Consequently, there may be a functional difference between the two main liver lobes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082590     DOI: 10.1007/s00535-005-1617-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  23 in total

Review 1.  Liver architecture.

Authors:  D Sasse; U M Spornitz; I P Maly
Journal:  Enzyme       Date:  1992

2.  The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid.

Authors:  B B BRODIE; H KURZ; L S SCHANKER
Journal:  J Pharmacol Exp Ther       Date:  1960-09       Impact factor: 4.030

3.  THEORY OF THE USE OF ARTERIOVENOUS CONCENTRATION DIFFERENCES FOR MEASURING METABOLISM IN STEADY AND NON-STEADY STATES.

Authors:  K L Zierler
Journal:  J Clin Invest       Date:  1961-12       Impact factor: 14.808

4.  Hepatic visualization on iodine-131 whole-body thyroid cancer scans.

Authors:  H A Ziessman; H Bahar; F H Fahey; V Dubiansky
Journal:  J Nucl Med       Date:  1987-09       Impact factor: 10.057

Review 5.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

6.  Gamma camera emission tomography. Development and properties of a multi-sectional emission computed tomography system.

Authors:  S A Larsson
Journal:  Acta Radiol Suppl       Date:  1980

7.  Streamlined flow in the portal vein: demonstration with MR angiography.

Authors:  Benoît P Gallix; Caroline Reinhold; Michel Dauzat; Patrice M Bret
Journal:  J Magn Reson Imaging       Date:  2002-05       Impact factor: 4.813

8.  Hepatic lobar differences in progression of chronic liver disease: correlation of asialoglycoprotein scintigraphy and hepatic functional reserve.

Authors:  S Matsuzaki; M Onda; T Tajiri; D Y Kim
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

9.  Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.

Authors:  U Dörr; K Wurm; E Höring; G Guzman; U Räth; H Bihl
Journal:  Horm Metab Res Suppl       Date:  1993

10.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

Authors:  E P Krenning; W H Bakker; P P Kooij; W A Breeman; H Y Oei; M de Jong; J C Reubi; T J Visser; C Bruns; D J Kwekkeboom
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

View more
  5 in total

1.  CT/99mTc-GSA SPECT fusion images demonstrate functional differences between the liver lobes.

Authors:  Tatsuaki Sumiyoshi; Yasuo Shima; Ryoutarou Tokorodani; Takehiro Okabayashi; Akihito Kozuki; Yasuhiro Hata; Yoshihiro Noda; Yoriko Murata; Toshio Nakamura; Kiminori Uka
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

Review 2.  Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging.

Authors:  Jeong Min Lee; Christoph J Zech; Luigi Bolondi; Eduard Jonas; Myeong-Jin Kim; Osamu Matsui; Elmar M Merkle; Michiie Sakamoto; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2011-07-22       Impact factor: 3.500

3.  Validation of control genes and a standardised protocol for quantifying gene expression in the livers of C57BL/6 and ApoE-/- mice.

Authors:  Priscilla E L Day; Karen F Chambers; Mark S Winterbone; Tatiana García-Blanco; David Vauzour; Paul A Kroon
Journal:  Sci Rep       Date:  2018-05-24       Impact factor: 4.379

4.  Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.

Authors:  Izumi Miki; Satoru Murata; Fumio Uchiyama; Daisuke Yasui; Tatsuo Ueda; Fumie Sugihara; Hidemasa Saito; Hidenori Yamaguchi; Ryusuke Murakami; Chiaki Kawamoto; Eiji Uchida; Shin-Ichiro Kumita
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

5.  Lobe-specific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasis.

Authors:  Andrea Ferrigno; Giuseppina Palladini; Alberto Bianchi; Vittoria Rizzo; Laura G Di Pasqua; Stefano Perlini; Plinio Richelmi; Mariapia Vairetti
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.